Maven Securities LTD Invests $415,000 in Aspen Aerogels, Inc. (NYSE:ASPN)

Maven Securities LTD bought a new position in Aspen Aerogels, Inc. (NYSE:ASPN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,000 shares of the construction company’s stock, valued at approximately $415,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Oppenheimer & Co. Inc. boosted its position in Aspen Aerogels by 167.2% during the third quarter. Oppenheimer & Co. Inc. now owns 102,535 shares of the construction company’s stock valued at $2,839,000 after purchasing an additional 64,154 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Aspen Aerogels during the third quarter valued at $1,342,000. Dakota Wealth Management acquired a new stake in Aspen Aerogels during the third quarter valued at $986,000. Rice Hall James & Associates LLC boosted its position in Aspen Aerogels by 19.9% during the third quarter. Rice Hall James & Associates LLC now owns 535,113 shares of the construction company’s stock valued at $14,817,000 after purchasing an additional 88,711 shares during the last quarter. Finally, Comerica Bank acquired a new stake in Aspen Aerogels during the first quarter valued at $1,992,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Price Performance

NYSE ASPN opened at $14.34 on Thursday. Aspen Aerogels, Inc. has a twelve month low of $10.36 and a twelve month high of $33.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.48 and a current ratio of 2.93. The stock has a market capitalization of $1.18 billion, a PE ratio of 1,434.00 and a beta of 2.12. The stock has a 50-day simple moving average of $19.18 and a 200 day simple moving average of $23.66.

Wall Street Analysts Forecast Growth

ASPN has been the topic of several recent research reports. Piper Sandler cut their target price on Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Benchmark reiterated a “buy” rating and set a $14.00 price target on shares of Aspen Aerogels in a research note on Thursday, August 8th. Barclays decreased their price target on Aspen Aerogels from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. StockNews.com upgraded Aspen Aerogels to a “sell” rating in a research note on Wednesday, November 13th. Finally, TD Cowen upped their price target on Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Aspen Aerogels has a consensus rating of “Moderate Buy” and an average price target of $28.70.

Insider Buying and Selling

In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the transaction, the chief executive officer now owns 483,640 shares of the company’s stock, valued at $14,523,709.20. This represents a 11.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is owned by insiders.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.